Atopic Clinical Trials in Berlin

13 recruitingBerlin, Germany

Showing 113 of 13 trials

Recruiting
Phase 2

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Janssen Research & Development, LLC180 enrolled62 locationsNCT07230860
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Dermatitis Atopic
Sanofi636 enrolled150 locationsNCT06241118
Recruiting
Phase 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled88 locationsNCT07105488
Recruiting
Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled67 locationsNCT07217015
Recruiting
Phase 1

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Sitryx Therapeutics Ltd149 enrolled14 locationsNCT07558668
Recruiting
Phase 2

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 3

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 2

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Novartis Pharmaceuticals84 enrolled28 locationsNCT07220577
Recruiting

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Atopic Dermatitis
Sanofi900 enrolled55 locationsNCT06039241
Recruiting
Not Applicable

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

Atopic Dermatitis (AD)
Société des Produits Nestlé (SPN)400 enrolled23 locationsNCT06943469
Recruiting

Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

Atopic Dermatitis
Charite University, Berlin, Germany25 enrolled1 locationNCT05098821
Recruiting

Atopy Network - Comprehensive Allergy Centers: Medical Care of Patients With Moderate to Severe Allergic Diseases

Atopic Disorders
Charite University, Berlin, Germany600 enrolled1 locationNCT05334940